S1:

**A** Clinical benefit rate (CBR)

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | Logistic model |
| Factor | Category | N | CBR (%) | OR (95% CI) | p |
| Route of administration  | Oral | 122 | 36.9 |  | 0.522 |
|  | i.v. | 128 | 41.4 |  |  |
|  |  |  |  |  |  |
| Platinum sensitivity | Sensitive | 117 | 47.9 | 2.30 (1.34 – 3.99) | 0.003 |
|  | Resistant | 133 | 31.6 |  |  |
|  |  |  |  |  |  |
| Number of previous therapy lines | >2 | 89 | 41.6 |  | 0.368 |
|  | ≤2 | 161 | 37.9 |  |  |
|  |  |  |  |  |  |
| Karnofski Index | <90 | 92 | 45.1 |  | 0.070 |
|  | ≥90 | 133 | 33.7 |  |  |
|  | missing | 25 |  |  | 0.061 |

**B** Time to progression (TTP)

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | Cox model |
| Factor | Category | N | TTP | HR (95%CI) | p |
| Route of administration | Oral | 122 | 3.5 |  | 0.506 |
|  | i.v. | 128 | 3.7 |  |  |
|  |  |  |  |  |  |
| Platinum sensitivity | Sensitive | 117 | 5.0 | 0.46 (0.34 – 0.63) | <0.0001 |
|  | Resistant | 133 | 2.8 |  |  |
|  |  |  |  |  |  |
| Number of previous therapy lines | >2 | 89 | 3.4 |  | 0.587 |
|  | ≤2 | 161 | 3.3 |  |  |
|  |  |  |  |  |  |
| Karnofski Index | <90 | 92 | 3.0 | 1.38 (1.02 – 1.86) | 0.039 |
|  | ≥90 | 133 | 4.3 |  |  |
|  | missing | 25 |  | 1.68 (1.00 – 2.80) | 0.048 |

**C** Overall Survival (OS)

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | Cox model |
| Factor | Category | N | OS | HR (95%CI) | p |
| Route of administration | Oral | 122 | 10.4 |  | 0.065 |
|  | i.v. | 128 | 13.6 |  |  |
|  |  |  |  |  |  |
| Platinum sensitivity | Sensitive | 117 | 12.8 |  | 0.156 |
|  | Resistant | 133 | 11.9 |  |  |
|  |  |  |  |  |  |
| Number of previous therapy lines | >2 | 89 | 10.6 |  | 0.228 |
|  | ≤2 | 161 | 12.9 |  |  |
|  |  |  |  |  |  |
| Karnofski Index | <90 | 92 | 8.6 | 1.93 (1.41 – 2.64) | <0.0001 |
|  | ≥90 | 133 | 15.1 |  |  |
|  | missing | 25 |  |  | 0.190 |